Drug intelligence / Profile preview

CD33.CAR(2A)CXCR4-CIK cells

Development stage: Preclinical
Lead developer: University of Milano-Bicocca
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CD33.CAR(2A)CXCR4-CIK cells is an experimental adoptive cell therapy consisting of cytokine-induced killer (CIK) cells engineered to co-express a chimeric antigen receptor (CAR) targeting CD33 and the chemokine receptor CXCR4. Developed primarily by researchers at the Tettamanti Research Center and the University of Milano-Bicocca, this therapy utilizes a bicistronic Sleeping Beauty transposon vector where the two components are linked by a 2A peptide. The CD33-targeting CAR provides antigen-specific cytotoxicity against CD33-positive acute myeloid leukemia (AML) blasts. The overexpression of CXCR4 is intended to restore bone marrow homing capabilities that are typically lost during ex vivo CIK cell expansion, thereby enhancing the eradication of leukemic stem cells within the bone marrow niche.

Other names: CD33.CAR(2A)CXCR4-CIKCD33 CAR-CXCR4 CIK cellsCD-33 CAR-CXCR4 CIK cellsCD 33 CAR-CXCR4 CIK cells

Targets

CD33 (Myeloid cell surface antigen CD33)CXCL12 (C-X-C motif chemokine ligand 12)

Beyond the preview

Go deeper on CD33.CAR(2A)CXCR4-CIK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD33.CAR(2A)CXCR4-CIK cells.

Explore the full profile